Life after ibrutinib? A new unmet need in CLL

Javier Pinilla-Ibarz1, Julio C Chavez1

  • 1MOFFITT CANCER CENTER.

Blood
|March 28, 2015
PubMed

Insights

Patients with chronic lymphocytic leukemia (CLL) experience poor outcomes after stopping ibrutinib treatment. Further research is needed to understand relapse and identify alternative therapies for CLL patients.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
  • Ibrutinib is an effective targeted therapy for CLL.
  • Discontinuation of ibrutinib can lead to disease progression.

Purpose of the Study:

  • To report on the outcomes of CLL patients after discontinuing ibrutinib.
  • To analyze the clinical course and prognostic factors in patients who stopped ibrutinib.

Main Methods:

  • Retrospective analysis of CLL patient data.
  • Evaluation of treatment patterns and outcomes post-ibrutinib discontinuation.

Main Results:

  • Patients exhibited poor outcomes, including disease progression and inferior survival, after stopping ibrutinib.
  • Relapse patterns and potential resistance mechanisms were observed.

Conclusions:

  • Discontinuation of ibrutinib is associated with adverse outcomes in CLL.
  • Further investigation into managing CLL post-ibrutinib is crucial.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
721
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
17.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K